2017- Received NIA/NIH funding to develop nanoantibodies against a novel dementia-related target with collaborators in Dr. Huaxi Xu's lab at Sanford Burnham Prebys Medical Discovery Institute
2017- Published an original research article in Applied Immunohistochemistry & Molecular Morphology demonstrating the utility of modified nanoantibodies "nAb Plus", in immunohistochemistry
2016- Received NHLBI/NIH grant to develop a large-scale stem cell production
2016- Received additional VC funding to develop iPSC-derived cell therapies in the fields of diabetes, spinal injury, and other diseases
2016- Published a protocol for cGMP production of iPSCs in Current Protocols in Stem Cell Biology
2016- Joined the Autism Consortium led by Dr. Gene Yeo at UCSD as part of the National Cooperative Reprogrammed Cell Research Groups (NCRCRG) under NIMH/NIH
2016- Acquired third building to expand research and development for Allele and the Scintillon Institute
2015- Licensed the intellectual property of Allele's feeder-free, integration-free, and xeno-free reprogramming technology using mRNAs of novel transcription factor combinations to Ocata, now under Astellas, the second largest Japanese pharmaceutical company, for developing cell treatment for macular degenderation
2015 - Purchased a 18,000 square foot building with cleanroom setup to accommodate Allele’s cGMP iPSC and stem cell derived tissues cells for future therapies
2015 – Formed formal drug development venture with high content screening company Vala Sciences and formally launched joint drug development service, which includes kinetic imaging and histology analysis
2015 – Closed the tranche 2 investment for business expansion. Established facilities for new laboratory space, animal care, and high throughput drug screening center for Allele and the Scintillon Institute
2015 – Recivedan NIA/NIH grant to develop nanoantibodies (nAb) against amyloid beta (Ab) in treating Alzheimer’s disease
2014- Received NIH SBIR grants on developing an all RNA platform for CRISPR genome modification (NIGMS) and creating nanoantibodies (nAb) against mRNA modification groups (NIDA)
2014 - Dr. Jiwu Wang co-authored a Nature Medicine article on using iPSCs for mitochondrial cardiomyopathy modeling with researchers with collaborators at Harvard led by Drs. William Pu, George Church, Ken Chien, Gordon Keller, Kit Parker, etc.
2013- Received a grant from NIDA/NIH to further improve mRNA reprogramming
2012 - Purchased a two-story building to convert it into a class A, molecular and cell biology laboratory to support R&D and new stem cell business
2012 - Published an original research paper describing a novel adipogenesis regulatory factor AFRO (or ADIRF for Adipogenesis Regulatory Factor designated by HUGO after our publication) and its functions in fat cell fate commitment
2012 - Founded the Scintillon Institute for bioengineering and bioimaging with Dr. Nathan Shaner for nonprofit research with long-term basic research projects for the advancement of science and benefits of human society
2012 - Developed novel mRNA-based reprogramming technologies, an effort led by Dr. Luigi Warren, which is published in Nature’s Scientific Reports and is the subject of a new patent application
2011 - Received and successfully executed a contract from the NIDA/NIH to develop novel technologies for isolating camelid antibodies
2011 - Launched a new web-based purchasing system
2011 - Filed patents: one using enzyme-based ratio enhancement for detection of genetic diseases using maternal blood DNA; the second using fluorescent proteins for skin protection
2011 - Expanded iPSC product line to include in vitro transcription template for introducing reprogramming or directed differentiation factor mRNAs
2010 - Received funding from NCI/NIH for shRNA screening in cancer-related DNA damage repair pathway
2010 - Received 3 grants on qualified therapeutics and diagnostics projects
2010 - Published original research paper and filed a patent application on photoconvertible fluorescent protein (mClav series)
2010 - Carried out glycosylated cancer antigen production project for NCI
2009 - Third US patent issued on siRNA and shRNA in the US
2009 - Publication in PLoSONE on RNA splicing regulator that can bind two different RNA targets at a distance or on different molecules
2009 - Introduction of Chromotek GFP-Trap and other camelid antibody products
2009 - Introduced of iPSC product line
2009 - Broad DNA-expressed RNAi patent issued in China
2008 - Successfully completed a cancer diagnostics antibody development contract for the National Cancer Institute, NIH in collaboration with AvantGen
2008 - Second US patent issued on broad use of engineered human and mouse U6 promoter to introduce siRNA or shRNA
2008 - Acquired Orbigen, Inc. and expanded product line to include about 1,000 antibodies and a baculovirus protein expression system
2007 - Licensed fluorescent proteins to leading drug companies
2007 - First US patent issued on DNA-driven RNAi technology
2007 - Accelerated customer services in antibody gene cloning and established cell lines for therapeutic companies
2006 - Moved to the Mesa Rim, San Diego facility in an expansion of business
2006 - Launched first fluorescent protein product
2005 - Became an end user market-oriented business by major expansions in new products, direct sales team, and professional customer service
2004 - Initiated the first ever RNAi workshop series in top universities around China through subsidiary company Allele China
2004 - Developed innovative systems for quantitative RNA detection
2003 - Received 2 more NIH grants to further develop Allele RNAi platform
2003 - Established custom services to carry out CRO projects
2002 - Patent-pending RNAi technology developed into LineSilence Kits
2002 - LineSilence Kits launched as the first DNA-based RNAi system, marketed through Promega
2001 - Received funding through 3 NIH SBIR grants
2001 - Launched oligo synthesis service
2001 - Filed for the first Pol III driven RNAi patent
